TNF and rheumatoid arthritis: In RA patients, people with the FcγRIIA risk variant are less responsive to the anti-TNFα drugs, infliximab and adalimumab, compared to people with the non-risk variant suggesting that the FcγRIIA genotype may be useful in predicting responses to therapy (12, 31).